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In an earlier study, levels of the proinﬂammatory cytokines TNF-α and IL-6 are higher in blisters ﬂuid from the complex regional
pain syndrome type 1 (CRPS1) side obtained at 6 and 30 months (median) after the initial event. The aim of this follow-up study
is to determine the involvement of these cytokines in long lasting CRPS1. Twelve CRPS1 patients, with median disease duration of
72months,participated.ThelevelsofTNF-αandIL-6weremeasuredinblisterﬂuid;diseaseactivitywasreevaluatedbymeasuring
pain and diﬀerences in temperature, volume, and mobility between both extremities. Diﬀerences in levels of IL-6 and TNF-α and
mobility between both sides were signiﬁcantly decreased. Pain and diﬀerences in temperature and volume were not signiﬁcantly
altered. No correlation was found between the cytokines and the disease characteristics. These results indicate that IL-6 and TNF-α
are only partially responsible for the signs and symptoms of CRPS1.
Copyright © 2008 Feikje Wesseldijk et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
Complex regional pain syndrome type 1 (CRPS1) is a disease
of an extremity that usually occurs as a complication after
surgery or trauma, although spontaneous occurrence is also
described [1].
The pathophysiology of CRPS1 is still not totally clear.
In general, three mechanisms are thought to be involved:
aﬀerent mechanisms (e.g., neurogenic inﬂammation) [2–4],
eﬀerent mechanisms (e.g., autonomic disturbances) [5], and
central nervous system mechanisms (e.g., cerebral plasticity)
[6]. Based on our review of the literature regarding the
CRPS pathophysiology, we hypothesized that following a
trauma or surgery, the normal sterile inﬂammatory response
runs out of control, and is perhaps initiated by a genetic
and/or acquired immunologic disorder [7]. Neuroimmune
activation of cells in the peripheral nervous system, which is
part of the aﬀerent mechanism, apparently results in central
sensitization and exacerbation of pain [8]. Neuropeptides,
cytokines, and other mediators are released during the
inﬂammation [9, 10] and cause the prominent signs and
symptoms, which resemble inﬂammation; these include
increased skin temperature, edema, pain, loss of function,
and redness [7, 11].
Levels of TNF-α and IL-6 were previously shown to be
elevated in ﬂuid of artiﬁcially induced skin blisters from the
CRPS1sideintheinitialstageofthedisease[9,12,13].These
observations suggest local inﬂammation. We hypothesized
that in most patients local inﬂammation would only be
present during the ﬁrst year of the disease, since the clinical
signs and symptoms of CRPS1 are expected to diminish
over time in most patients. Therefore, we predicted that
the formation of proinﬂammatory mediators (such as IL-6
and TNF-α) should decline during the course of the disease.
In an earlier study, we showed that although the levels of
TNF-α and IL-6 declined in the intermediate stage of the
disease, they were still signiﬁcantly elevated in the CRPS1
extremity [13]. In the present study, we examine whether
this decline in cytokine levels continues during the course
of the disease and whether this decline is correlated with
a possible improvement in disease activity as measured by
registrationofpain,andbythemeasurementofdiﬀerencesin
temperature, volume, and mobility between the CRPS1 and
contralateral extremities.2 Mediators of Inﬂammation
2. MATERIALS AND METHODS
The protocol was approved by the medical ethics committee
oftheErasmusMCRotterdam(MECno.1989.780/2001/24).
Guidelines according to the Declaration of Helsinki
(amended version of 2002) and Good Clinical Practice
(ICH/GCP version 1996) were followed. Data collection
and calculations were performed according to guidelines for
registration of personal data.
2.1. Patients
Sixty-six patients with CRPS1 in one extremity for 7
months after the initial event participated in several studies
conducted between April 2001 and February 2004 (T0) to
investigate the pathophysiology of CRPS1 or the eﬀects of
speciﬁc treatments for CRPS1 [9, 12, 14]. At the time of the
ﬁrst follow-up study in 2004, 25 patients with CRPS1 with a
median disease duration of 30 months after the initial event
agreed to participate (T1) [13]. In 2007, these 25 patients
were again asked to participate. One patient had died, one
patient appeared to have CRPS type 2, and 11 patients chose
not to participate again. In the end, 12 patients with CRPS1
were included in this study (T2).
For this study, we used the results obtained at baseline
(T0), ﬁrst follow-up measurement (T1), and second follow-
up measurement (T2) from only these 12 patients. All 12
patients fulﬁlled the CRPS1 criteria by Bruehl et al. [15]
at the ﬁrst measurement (T0), performed shortly after the
initial event (median 4 months) which resulted in the
development of the disease.
2.2. Painassessment
The intensity of pain was assessed by using a visual analoge
scale (VAS) recorded in 0–100 millimeters [16]. The McGill
Pain Questionnaire, Dutch Language version (MPQ-DLV),
was measured by counting the total number of words chosen
from 20 items [17].
2.3. Temperaturemeasurement
Skin temperature was measured using an infrared tympanic
probe thermometer, First Temp Genius (Sherwood Medical,
Crawley, Sussex, UK) [18]. Measurements were obtained on
the dorsal aspect of the hand in a matrix of ﬁve points.
The diﬀerence in mean temperature between the CRPS1 and
contralateral extremities was calculated, and the data were
expressed with respect to the temperature of the unaﬀected
hand.
2.4. Assessmentofvolume
V o l u m ew a sm e a s u r e dw i t hav o l u m e t e r ,w h i c hm e a s u r e s
the amount of water displaced by immersion of a body part
[19]. The diﬀerence between the CRPS1 and contralateral
extremitieswascalculatedasapercentageofthecontralateral
extremity.
2.5. Assessmentofmobility
Mobility was assessed by measuring the active range of
motion (AROM), which is deﬁned as the arc of motion
requiring muscle power to achieve the motion of a joint [20,
21]. The AROM on the CRPS1 extremity was multiplied by
100 and divided by the AROM on the contralateral extremity
to derive the percentage of normal mobility.
2.6. Blisters
Artiﬁcial skin blisters were induced using a suction method
[9, 14, 22]. A skin suction chamber was positioned on the
skin of the CRPS1 and contralateral extremities. A vacuum
of300mmHgwasappliedwithanAtmoforte350Aaspirator
pump(ATMOSMedizintechnik, Lenzkirch,Germany).After
15 minutes, the vacuum was reduced to 250mmHg, and
after another 15 minutes it was reduced to 200mmHg.
This negative pressure was maintained for 2–2.5 hours. The
blisters created were punctured, and ﬂuid was pooled from
each side into a 1.5mL Eppendorf conical polypropylene
tube and centrifuged for 5 minutes at 1600 × g. All samples
were stored in 1mL conical polypropylene tubes at −80◦C
until analysis [9, 22].
2.7. Cytokineassays
Blister ﬂuid samples were diluted 4-fold in appropriate
calibrator dilutent assay buﬀer for the direct measurement
of cytokines. Cytokine assays were performed following
the manufacturer’s protocol, PeliKine human ELISA kits
for IL-6 [M1906] and TNF-α [M1920] (CLB, Amsterdam,
the Netherlands). The standard curve ranges and mean
calculated zero signal ±3 (SD) were 0–80 and 0.3pg/mL for
IL-6and0–1000and1pg/mLforTNF-α.Theabsorbanceper
well was measured at 450nm with a Medgenix EASIA reader.
Sample concentrations were calculated using the appropriate
standard calibration lines and the Softmax software of the
reader.
2.8. Statisticalanalysis
Data were analyzed with SPSS for Windows, version 14.0. To
determine whether the 12 CRPS1 patients from this study
were a representative group of the initial 66 CRPS1 patients
who started the follow-up study, the one-way ANOVA
test was used for a comparison between groups for the
proinﬂammatory cytokines, and the outcome parameters
pain, temperature, volume, and mobility. To determine if
the diﬀerences in means for these selected parameters were
signiﬁcantly diﬀerent from 0, we applied the one-sample t-
test for comparisons of the levels of the proinﬂammatory
cytokines between both extremities, and to the diﬀerences
in the outcome parameters of temperature, volume, and
mobility. Mixed model analysis was used to compare the
diﬀerences between both extremities to each other for the
levels of the cytokines, VAS, McGill, temperature, volume,
and mobility between each time point. Correlations between
the diﬀerences in levels of IL-6 and TNF-α and the outcomeFeikje Wesseldijk et al. 3
Table 1: Characteristics of the study population.
Patient characteristic Value
Gender: male/female 3/9
Side: right/left 6/6
Cause: fracture/accident/surgery/spontaneous 6/2/4/0
T0 T1 T2
Age in years 52 (48–56) 54 (51–58) 57 (54–62)
Duration of CRPS1 in months 4 (3–14) 35 (21–48) 72 (59–86)
Disease-related medication (number of patients)
Nonsteroid anti-inﬂammatory drugs (NSAIDs) 6 1 0
Opiates 4 2 2
Antioxidants 8 1 0
Vasodilators 1 0 0
Muscle relaxants 1 0 0
Antidepressants 1 1 0
Benzodiazepines 2 0 0
Antiepileticum 1 0 1
Data are presented as the n or median (interquartile range).
Table 2: Levels of IL-6 and TNF-α in blister ﬂuid obtained from the CRPS1 and contralateral extremities at ﬁrst measurement (T0), second
measurement (T1), and third measurement (T2). Data are presented as mean (range).
T0 T1 T2
CRPS1 Contralateral CRPS1 Contralateral CRPS1 Contralateral
IL-6 (pg/mL) 116∗ (5–662) 8 (1–36) 80∗ (1–346) 2 (0–5) 22 (4–78) 20 (3–61)
TNF-α (pg/mL) 66∗ (1–359) 31 (1–258) 56∗ (3–176) 16 (2–80) 38 (9–81) 47 (10–142)
∗Wilcoxon signed ranks test P<. 05 (CRPS1 versus contralateral).
parameters were calculated using the Pearson correlation
test. Signiﬁcance was accepted at the P<. 05 (two-sided)
level.
3. RESULTS
The group of 12 CRPS1 patients was a good representation
of the original group of 66 CRPS1 patients with which we
initiated the follow-up study 6 years ago. The groups were
equal for diﬀerence in levels of IL-6 (P = .60) and TNF-
α (P = .72). They were also equal for the McGill pain
score (P = .41), temperature diﬀerence (P = .41), volume
diﬀerence (P = .48), and mobility (P = .38). The two groups
wereonlysigniﬁcantlydiﬀerentfromeachotherforVASpain
(P = .03). The characteristics and medication use of the 12
patients with CRPS1 in one extremity for 6 years (median)
who were examined 3 times during the follow-up of their
CRPS1 are presented in Table 1.
The IL-6 and TNF-α levels in blister ﬂuid at all time
intervals are presented in Table 2.T h ed i ﬀerences in levels of
IL-6 between both extremities did not signiﬁcantly change
at T1 compared to T0 (P = .531) and at T2 compared
to T0 (P = .063). However, the diﬀerences in levels did
signiﬁcantly decrease at T2 compared to T1 (P = .028). The
diﬀerences in levels of TNF-α between both extremities did
notsigniﬁcantlychangeatT1comparedtoT0(P = .892)and
at T2 compared to T0 (P = .153). The decrease in diﬀerences
from T1 to T2 almost reached signiﬁcance (P = .064). At the
T0 and T1 measurement, the diﬀerence in levels of IL-6 and
TNF-α between the CRPS1 side and the contralateral side
in blister ﬂuid was signiﬁcantly diﬀerent from 0. However,
at the T2 measurement, no signiﬁcant diﬀerences between
the two sides were evident (Figures 1(a) and 1(b)) for the 12
CRPS1 patients.
Also the signs and symptoms of impairment were
measured at T0, T1, and T2 in terms of pain and diﬀerences
in temperature, volume, and mobility between the CRPS1
and the contralateral extremities. The VAS pain did not
signiﬁcantly change during the course of the disease in these
12 patients (P = .472). The McGill pain score improved
signiﬁcantly at T1 compared to T0 (P = .006), but pain
was signiﬁcantly worse at T2 compared to T1 (P = .041).
Furthermore, no signiﬁcant improvement was seen at T2 as
compared to T0 (P = .567). The VAS pain and the McGill
pain score signiﬁcantly diﬀered from 0 during all 6 years of
follow-up (Figures 2(a) and 2(b)).
T h ea b s o l u t ed i ﬀerence in temperature and volume
between both sides did not change during the course
of the disease (P = .204 and P = .509, resp.). The
diﬀerence between the CRPS1 and contralateral side did vary4 Mediators of Inﬂammation
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Figure 1: Diﬀerences in levels of IL-6 and in TNF-α in blister ﬂuid between the CRPS1 and contralateral extremities over the course of
CRPS1. Blister ﬂuid was collected as described in materials and methods (see Section 2) and IL-6 (panel a) and TNF-α (panel b) levels
(pg/mL) in the CRPS1 and the contralateral limbs were measured by ELISA. The data obtained from the same 12 patients at each time
period are expressed as the diﬀerence in IL-6 or TNF-α levels between the two sides (log pg/mL). Each time point shows the mean ± the
standard deviation. The P values represent the deviation from no diﬀerence (0).
signiﬁcantly from 0 at all three moments of measurement for
temperature and volume (Figures 2(c) and 2(e)). Mobility
improved signiﬁcantly at T1 and T2 as compared to T0
(P = .002 for both), with no signiﬁcant increase in AROM
at T2 compared to T1 (P = .353). The diﬀerence in mobility
between both sides was signiﬁcantly diﬀerent from 0 at
T0 and T1, but no signiﬁcant diﬀerence was found at T2
(Figure 2(e)).
No correlation was found between the diﬀerences in
levels of the proinﬂammatory cytokines and the other
disease-related parameters pain and diﬀerences between
both extremities for temperature, volume, and mobility
during the course of the disease.
The total use of disease-related medication was divided
in 8 categories (see Table 1). The total number of patients
usingmedicationaswellasthevarietyintypesofmedication
decreased during the course of the disease.
4. DISCUSSION
Inasixyearsfollow-upstudyin12CRPS1patients,wefound
a decrease in the extent of the diﬀerences in levels of TNF-α
and IL-6 in blister ﬂuid. After disease duration of 4 months
(T0) and of 3 years (T1), the levels of these cytokines were
signiﬁcantly higher in the CRPS1 extremity compared to
the contralateral extremity. However, after 6 years (T2) the
diﬀerences in the cytokine levels between the two extremities
were not signiﬁcantly diﬀerent. In contrast, the diﬀerence in
mobility between both sides was signiﬁcantly improved after
6 years. Pain and the diﬀerences in temperature and volume
werenotsigniﬁcantlyalteredduringthecourseofthedisease.
No correlation was found between the proinﬂammatory
cytokines and the disease characteristics.
Because TNF-α and IL-6 are proinﬂammatory cytokines,
one might expect that these markers of inﬂammation would
be directly related to the characteristics of inﬂammation:
pain, temperature increase, edema, and loss of function. In
this study, the levels of TNF-α and IL-6 were diminished
during the course of the disease, but no clear improvement
of inﬂammatory signs was found. Most of the 12 patients
still reported much pain. The VAS score did not change
during the course of the disease, and while the McGill
Pain score improved at ﬁrst, it worsened again at the third
measurement. The absolute temperature diﬀerence tended
to diminish during the course of the disease; however, this
was not signiﬁcant. The volume diﬀerence also did not
change signiﬁcantly during the course of the disease. Only
the AROM improved signiﬁcantly after 6 years; the patients
only described some stiﬀness of the joints.
No improvement of the signs and symptoms of inﬂam-
mationwasfoundasdescribedabove,howeveraftersixyears,
a decline in the number of patients using medication that
could counteract inﬂammation has been observed, such as
NSAIDs, opiates, and antioxidants. We concluded that the
normalization of inﬂammatory mediators after six years was
not aﬀected through pharmacological intervention, but due
to a diminution of disease activity.
An explanation for a decrease in diﬀerences in the levels
of TNF-α and IL-6 between both sides during the course of
CRPS1 is a spreading of the disease from the CRPS1 side
to the contralateral extremity. This spreading could also be
explained by the fact that the levels in the CRPS1 side are
increased during the course of the disease. However, theFeikje Wesseldijk et al. 5
0
10
20
30
40
50
60
70
80
90
100
V
i
s
u
a
l
a
n
a
l
o
g
e
s
c
a
l
e
(
0
–
1
0
0
m
m
,
n
o
p
a
i
n
-
m
o
s
t
p
a
i
n
)
T0 T1 T2
P = 0 P = .002 P = .001
Followup moment
(a)
0
2
4
6
8
10
12
14
16
18
20
M
c
G
i
l
l
p
a
i
n
q
u
e
s
t
i
o
n
n
a
i
r
e
(
n
u
m
b
e
r
o
f
w
o
r
d
s
c
h
o
s
e
n
,
0
–
2
0
)
T0 T1 T2
P = 0 P = .01 P = .001
Followup moment
(b)
0
1
2
3
A
b
s
o
l
u
t
e
d
i
ﬀ
e
r
e
n
c
e
i
n
t
e
m
p
e
r
a
t
u
r
e
b
e
t
w
e
e
n
t
h
e
C
R
P
S
1
a
n
d
c
o
n
t
r
a
l
a
t
e
r
a
l
e
x
t
r
e
m
i
t
y
(
◦
C
)
012
P = .006 P = .017 P = .011
Followup moment
(c)
0
2
4
6
8
10
12
A
b
s
o
l
u
t
e
d
i
ﬀ
e
r
e
n
c
e
i
n
v
o
l
u
m
e
b
e
t
w
e
e
n
t
h
e
C
R
P
S
1
a
n
d
c
o
n
t
r
a
l
a
t
e
r
a
l
e
x
t
r
e
m
i
t
y
(
%
o
f
c
o
n
t
r
a
l
a
t
e
r
a
l
s
i
d
e
)
012
P = .007 P = .003 P = .005
Followup moment
(d)
−50
−40
−30
−20
−10
0
10
D
i
ﬀ
e
r
e
n
c
e
i
n
A
R
O
M
b
e
t
w
e
e
n
t
h
e
C
R
P
S
1
a
n
d
c
o
n
t
r
a
l
a
t
e
r
a
l
e
x
t
r
e
m
i
t
y
(
%
o
f
c
o
n
t
r
a
l
a
t
e
r
a
l
s
i
d
e
)
T0 T1 T2
P = .002 P = .049 P = .122
Followup moment
(e)
Figure 2: The assessment of pain over the course of CRPS1 disease as measured by the Visual Analogue Scale is shown in panel (a). Panel (b)
showstheassessmentofpainasmeasuredbytheMcGillPainQuestionnaire.Panel(c),(d),and(e),respectively,showtheabsolutediﬀerences
in skin surface temperature, the absolute diﬀerences in volume, and the diﬀerences in AROM between the CRPS1 and contralateral sides
in CRPS1 patients over the course of disease. The data obtained from the same 12 patients at the 3 points of measurement were collected
as described in materials and methods and are expressed as the mean ± standard deviation. The P values represent the deviation from no
diﬀerence (0).6 Mediators of Inﬂammation
increased levels of the contralateral side measured 6 years
aftertheinitialeventdonotevencomeclosetothehighlevels
of TNF-α and IL-6 measured in the CRPS1 side 4 months
and 3 years after the initial event. Furthermore, the levels of
IL-6 of both sides at T2 are within the normal range of the
levels measured in blister ﬂuid from healthy controls (mean
16pg/mL) [23]. These ﬁndings do not support the theory
of spreading. Finally, one would expect that the diﬀerences
between both sides in disease activity would decrease during
the course of the disease when there is spreading. This is not
conﬁrmed in this follow-up study.
In the present study, in contrast with the diminished
levels of the proinﬂammatory cytokines during the course
of the disease, signs of inﬂammation were found in all
three stages of the disease. In an earlier study, during the
ﬁrst two years of CRPS1, about half of the patients showed
no inﬂammatory signs [24], but did fulﬁl the criteria of
Bruehl et al. [15]. Several other studies conﬁrmed that
observation, even describing a primarily cold CRPS1 [4, 10,
25, 26].
An explanation for ﬁnding a temperature increase and
decrease already at the onset of CRPS1 is that blood ﬂow;
and thus changes in skin temperature are the results of not
only aﬀerent mechanisms, such as local mediators, but also
eﬀerent mechanisms. Disturbances in central temperature
regulation could result in altered (local) temperature of
the injured extremity [27–29]. Recently, we found evidence
that temperature changes also might be partly caused by
the crosstalk in the vascular system between higher levels
of cytokines and the nitric oxide/endothelin-1 (NO/ET-1)
balance [30, 31]. Furthermore, blood ﬂow and tissue-blood
distribution could be diminished, partly due to disuse of the
extremity [13].
A possible explanation for ﬁnding edema and atrophy
during all stages of the disease is that edema is not only
aﬀected by TNF-α and IL-6, but also by other inﬂammatory
mediators such as calcitonin gene-related peptide (CGRP)
and substance P (SP), and related mechanisms [32, 33].
No correlation was found between the diﬀerences in
levels of the cytokines and pain and diﬀerences between
both extremities for temperature, volume, and AROM for
all three times of measurement. In an earlier study, we
found similar results [24]. Perhaps IL-6 and TNF-α are only
partially responsible for the permanent damage in CRPS1,
expressed as pain, and changes in temperature, volume, and
mobility. Other mediators or a combination of mediators,
suchasnitric oxide [30]and/oraminoacids [34,35] or other
mechanisms [7], may also play a role in the pathophysiology
of CRPS1 and may explain in part the course of the disease.
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